Compound with PPAR-γ agonist activity. The drug rescues neurodegeneration in FRDA through restoration of mitochondrial membrane potential, improvement of mitochondrial function, and calcium homeostasis. It also improved motor function in frataxin -deficient mice. The gene discussed is FXN; the disease is Friedreich ataxia.